Janux Therapeutics (NASDAQ:JANX) Releases Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Janux Therapeutics (NASDAQ:JANX) posted its quarterly earnings data on Thursday. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.14, FiscalAI reports.

Janux Therapeutics Trading Up 0.7%

Janux Therapeutics stock traded up $0.10 during mid-day trading on Thursday, reaching $13.80. The company’s stock had a trading volume of 724,303 shares, compared to its average volume of 1,104,011. Janux Therapeutics has a twelve month low of $12.12 and a twelve month high of $35.34. The business has a 50 day moving average price of $13.73 and a 200-day moving average price of $20.80. The firm has a market cap of $830.07 million, a price-to-earnings ratio of -8.21 and a beta of 2.88.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Bank of America lowered their price objective on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Cantor Fitzgerald decreased their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research report on Tuesday, December 2nd. Clear Str lowered shares of Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a report on Thursday, January 22nd. Finally, HC Wainwright decreased their price objective on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating for the company in a report on Tuesday, December 2nd. Eleven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $60.08.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 1,879 shares of the firm’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total value of $25,798.67. Following the transaction, the insider directly owned 83,095 shares in the company, valued at approximately $1,140,894.35. This trade represents a 2.21% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Thomas Diraimondo sold 2,505 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $34,393.65. Following the sale, the insider directly owned 124,425 shares of the company’s stock, valued at approximately $1,708,355.25. This represents a 1.97% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 22,366 shares of company stock valued at $371,245 in the last ninety days. 8.10% of the stock is owned by insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in JANX. Osaic Holdings Inc. boosted its position in Janux Therapeutics by 704.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,468 shares of the company’s stock valued at $80,000 after purchasing an additional 3,037 shares during the period. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 175.5% in the second quarter. Tower Research Capital LLC TRC now owns 3,928 shares of the company’s stock valued at $91,000 after buying an additional 2,502 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Janux Therapeutics by 185.1% during the second quarter. BNP Paribas Financial Markets now owns 7,673 shares of the company’s stock valued at $177,000 after acquiring an additional 4,982 shares during the period. AQR Capital Management LLC grew its position in shares of Janux Therapeutics by 71.7% during the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock worth $262,000 after acquiring an additional 4,059 shares during the last quarter. Finally, Jain Global LLC acquired a new stake in shares of Janux Therapeutics in the 3rd quarter worth about $241,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.